Vericel (VCEL) Competitors $34.27 +0.68 (+2.02%) As of 03:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VCEL vs. ABVX, CRSP, NUVL, AXSM, LEGN, TGTX, PCVX, MTSR, KRYS, and PTCTShould you be buying Vericel stock or one of its competitors? The main competitors of Vericel include Abivax (ABVX), CRISPR Therapeutics (CRSP), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Legend Biotech (LEGN), TG Therapeutics (TGTX), Vaxcyte (PCVX), Metsera (MTSR), Krystal Biotech (KRYS), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry. Vericel vs. Its Competitors Abivax CRISPR Therapeutics Nuvalent Axsome Therapeutics Legend Biotech TG Therapeutics Vaxcyte Metsera Krystal Biotech PTC Therapeutics Vericel (NASDAQ:VCEL) and Abivax (NASDAQ:ABVX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability. Which has better valuation & earnings, VCEL or ABVX? Vericel has higher revenue and earnings than Abivax. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVericel$237.22M7.38$10.36M$0.12289.21AbivaxN/AN/A-$190.71MN/AN/A Is VCEL or ABVX more profitable? Vericel has a net margin of 2.85% compared to Abivax's net margin of 0.00%. Vericel's return on equity of 2.47% beat Abivax's return on equity.Company Net Margins Return on Equity Return on Assets Vericel2.85% 2.47% 1.69% Abivax N/A N/A N/A Do insiders and institutionals have more ownership in VCEL or ABVX? 47.9% of Abivax shares are owned by institutional investors. 5.2% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor VCEL or ABVX? In the previous week, Vericel had 2 more articles in the media than Abivax. MarketBeat recorded 16 mentions for Vericel and 14 mentions for Abivax. Abivax's average media sentiment score of 0.53 beat Vericel's score of 0.12 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 3 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Abivax 3 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, VCEL or ABVX? Vericel has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, Abivax has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Do analysts recommend VCEL or ABVX? Vericel presently has a consensus price target of $58.40, suggesting a potential upside of 68.28%. Abivax has a consensus price target of $114.25, suggesting a potential upside of 23.13%. Given Vericel's higher possible upside, equities analysts clearly believe Vericel is more favorable than Abivax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vericel 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71Abivax 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.91 SummaryVericel beats Abivax on 9 of the 13 factors compared between the two stocks. Get Vericel News Delivered to You Automatically Sign up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCEL vs. The Competition Export to ExcelMetricVericelMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.77B$3.39B$6.15B$10.47BDividend YieldN/A2.30%5.73%4.78%P/E Ratio292.0722.9785.0727.24Price / Sales7.38435.83573.51178.32Price / Cash110.8546.1137.3961.86Price / Book5.8610.5212.426.70Net Income$10.36M-$52.47M$3.32B$276.79M7 Day Performance5.90%-0.06%0.28%-0.86%1 Month Performance4.44%15.60%10.06%6.26%1 Year Performance-15.91%15.29%72.23%37.64% Vericel Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCELVericel3.3101 of 5 stars$34.27+2.0%$58.40+70.4%-19.9%$1.73B$237.22M285.27300Trending NewsAnalyst UpgradeAnalyst RevisionABVXAbivax3.0125 of 5 stars$86.67+3.3%$103.29+19.2%+908.5%$6.34BN/A0.0061Analyst ForecastHigh Trading VolumeCRSPCRISPR Therapeutics1.6482 of 5 stars$70.19+3.6%$71.50+1.9%+49.5%$6.16B$37.31M-12.93460News CoverageAnalyst ForecastInsider TradeNUVLNuvalent2.9312 of 5 stars$83.85-0.4%$118.89+41.8%-12.5%$6.07BN/A-17.1140Trending NewsAnalyst ForecastInsider TradeAXSMAxsome Therapeutics4.6942 of 5 stars$119.94-0.3%$177.93+48.4%+49.9%$6.00B$385.69M-23.66380Analyst RevisionLEGNLegend Biotech2.7978 of 5 stars$31.44-1.9%$74.22+136.1%-24.9%$5.92B$627.24M-35.732,609News CoverageGap UpTGTXTG Therapeutics4.403 of 5 stars$36.76+0.1%$49.00+33.3%+42.7%$5.82B$329M99.35290Positive NewsPCVXVaxcyte2.3021 of 5 stars$41.21-3.4%$106.25+157.8%-62.0%$5.54BN/A-10.03160News CoverageAnalyst ForecastMTSRMetseraN/A$52.50+1.2%$55.75+6.2%N/A$5.45BN/A0.0081KRYSKrystal Biotech4.3725 of 5 stars$180.57-1.5%$209.00+15.7%+8.1%$5.31B$290.52M36.70210News CoverageAnalyst RevisionPTCTPTC Therapeutics3.3822 of 5 stars$64.80-0.9%$69.00+6.5%+82.4%$5.19B$1.76B9.301,410Analyst Revision Related Companies and Tools Related Companies ABVX Competitors CRSP Competitors NUVL Competitors AXSM Competitors LEGN Competitors TGTX Competitors PCVX Competitors MTSR Competitors KRYS Competitors PTCT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VCEL) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vericel Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Vericel With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
